All In Biotech

Drug Trial Radar · NCT05019521

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Last checked: Nov 20, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

365

Actual

Start

Aug 23, 2021

Primary completion

Jul 5, 2024

Study completion Jan 21, 2025

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

Conditions

  • Geographic Atrophy

Interventions

  • DanicopanDrug

    Oral tablet.

  • PlaceboDrug

    Oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF)Time frame: Baseline, Week 52

Locations

128 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Beverly Hills, California

  • Research Site

    Encino, California

  • Research Site

    Fresno, California

  • Research Site

    Fullerton, California

  • Research Site

    La Jolla, California

  • Research Site

    Pasadena, California

  • Research Site

    Sacramento, California

  • Research Site

    San Mateo, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Longmont, Colorado

  • Research Site

    Waterford, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    Deerfield Beach, Florida

  • Research Site

    Naples, Florida

  • Research Site

    Palm Beach Gardens, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    New Albany, Indiana

  • Research Site

    West Des Moines, Iowa

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Rosedale, Maryland

  • Research Site

    Towson, Maryland

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Southaven, Mississippi

  • Research Site

    Reno, Nevada

  • Research Site

    Teaneck, New Jersey

  • Research Site

    Great Neck, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Springfield, Oregon

  • Research Site

    Kingston, Pennsylvania

  • Research Site

    Monroeville, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Greenville, South Carolina

  • Research Site

    Ladson, South Carolina

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.